Search results
Results from the WOW.Com Content Network
The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the ...
For premium support please call: 800-290-4726 more ways to reach us
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our ...
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
While not a mind-blowing move, it is good to see that the Editas Medicine, Inc. (NASDAQ:EDIT) shar... Help shape the future of investing tools and you could win a $250 gift card!
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us